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Propylthiouracil (PTU) was introduced for clinical use in July 1947 for Graves’ disease (GD) treatment. Over the 60 years that this
medication has been used, reports of PTU-related liver failure and death have accumulated. On October 28, 2008, an expert panel
evaluated PTU drug safety in children at the Eunice Kennedy Shriver National Institute of Child Health and Human Development
(NICHD) It is estimated that about 4000 pediatric patients per year with GD are being treated with antithyroid drugs (ATDs) in
the United States, and up to 30% of pediatric patients with GD are being treated with PTU. The risk of severe PTU-induced liver
failureisestimatedas1in2000–4000children.ThenumberofchildrendevelopingreversiblePTU-inducedliverinjuryisestimated
to be at least 1 in 200. Routine biochemical surveillance of liver function and hepatocellular integrity is not useful in identifying
children who will develop liver failure. Children appear to be at higher risk for PTU-induced liver injury than adults. PTU should
not be used as ﬁrst line therapy for the treatment of GD in children. Current PTU use in children taking this medication should
be stopped in favor of alternate therapies.
Copyright © 2009 S. A. Rivkees and D. R. Mattison. This is an open access article distributed under the Creative Commons
Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is
properly cited.
1.Propylthiouracil
Graves’ disease (GD) is the most common cause of hyper-
thyroidism and is treated with antithyroid drugs (ATDs),
radioactive iodine, or surgery [1]. In the pediatric popu-
lation, the ATDs propylthiouracil (PTU) and methimazole
(MMI) are widely used as ﬁrst line therapy, with many
children treated with ATDs for extended periods [1].
Propylthiouracil (6-propyl-2-thiouracil), was introduced
for clinical use in July 1947 and has played a seminal
role in the treatment of hyperthyroidism [2, 3]. PTU
acts by inhibiting the enzyme thyroperoxidase, which adds
iodide to tyrosine residues on the thyroxine hormone
precursor thyroglobuoine [4]. PTU also inhibits the enzyme
tertaiodothyronine 5  deiodinase, which converts thyroxine
(T4) to triiodothyronine (T3) [5].
Whereas countless individuals have beneﬁted from PTU
therapy, over the 60 years that this medication has been used,
reports of PTU-related liver failure and death in children
and adults have accumulated [6, 7] .T h e s eo b s e r v a t i o n sr a i s e
majorconcernsaboutthesafetyofthismedication,especially
in children.
2.CaseReports
Twenty nine cases of PTU-induced liver failure have been
reported in individuals with ages ranging between 6 and 62
years [8–42]. Recovery from liver failure without transplant
occurred in 18 individuals, transplantation occurred in 3
persons, and 9 deaths were reported. Of these cases, 14
were pediatric patients [8, 12, 14, 21, 22, 25, 26, 29, 31,
35, 37, 39, 41, 43]( Table 1). There were three deaths in
PTU-treatedpediatricpatients.Fivechildrenwhounderwent
liver transplantation have been reported.
In comparison with reports of PTU-induced hepatocel-
lular necrosis, liver-related problems associated with MMI
use are related to cholestasis, which has been reported in
20 adults [44–53]. MMI-related cholestasis is associated with
high doses and older age [51]. There is one case report of
MMI-related liver failure leading to death in a 43-year-old
manwithhyperthyroidismandhepatitisB[54].Thedeathof
a20-year-oldwomantreatedwith90mg/dayofmethimazole
for eight months has been reported [26].
We are unaware of reports of MMI-related liver failure,
liver transplants, or deaths in pediatric patients.2 International Journal of Pediatric Endocrinology
3. Adverse Event Reports
Data from 48 US Food and Drug Administration (FDA)
reports and ATD-related adverse event (AE) reports in
individuals <18 years of age from 1970 to 1997 were available
as part of a previous analysis of pediatric GD treatment [55].
Thirty-four reports were related to PTU; 14 reports were
related to MMI (Table 2).
PTU-related AEs included rashes, leukopenia, arthritis,
vasculitis, liver injury, and death. PTU was associated with
hospitalization in 18 children. Liver injury was reported in
18 patients. The time from onset of therapy until recognized
liverinjurywas1to23months.Renalfailureduetovasculitis
was reported in three children taking PTU.
MMI-related AEs included rashes, urticaria, arthralgias,
and vasculitis. There were no reports of liver or renal
injury.MMI-relatedAEswereassociatedwithhospitalization
in three children. There were no reports of MMI-induced
liver failure, liver transplants, or deaths.
4. Cohort Studies
Studies reporting outcomes of pediatric GD treated with
PTU, in which AEs were discussed, were evaluated [56–
62]( Table 3). These cohorts included more than 550 PTU-
treated patients. AEs related to PTU use occurred in 15 to
35% of children, except for one report that described AEs in
1o f6 3p a t i e n t s .
Cohort studies describing AEs related to MMI are few.
In a recent study of the MMI analog carbimazole, of 147
treated children, eight children developed rashes, and one
child developed agranulocytosis [58].
5. LiverTransplantationData
In 2004, drug-induced liver injury was reported to account
for 15% of liver transplants in the Organ Procurement
and Transplantation Network (OPTN) and United Network
for Organ Sharing (UNOS) database [64]. Acetaminophen
accounted for 50% of drug-related transplants, followed by
isoniazid (17%) [64]. PTU was the third most common
cause of drug-induced liver failure, accounting for 10% of
drug-related transplants [64] .T h ea g er a n g eo fP T U - r e l a t e d
transplant recipients was 6 to 69 years [64].
As of September 22, 2008, data from OPTN and UNOS
reveal a total of 23 PTU-related liver transplants from
1990 to 2007. 30% of liver transplant recipients were pedi-
atric patients (Table 4). No MMI-related liver transplants
occurred over this period in either children or adults.
6.NICHD,OPPBWorkshop
The above concerns about a PTU safety were relayed to
the NICHD Obstetric and Pediatric Pharmacology Branch
(OPPB) [7]. Under the umbrella of the Best Pharmaceuticals
for Children Act (information on BPCA is available at:
http://bpca.nichd.nih.gov/), a workshop was held at the
Eunice Kennedy Shriver National Institute of Child Health
and Human Development (NICHD) on October 28, 2008 to
evaluate PTU drug safety in children.
Workshop participants included members of the NIH
and FDA and experts in thyroidology, pediatric endocrinol-
ogy, hepatology, epidemiology, and adverse event surveil-
lance. Speakers included Vicky Border-Hemphill, Pharm D
(FDA), James Boyer, M.D. (Yale University), Wida Cerikh,
Ph.D.(UnitedNetworkforOrganSharing),DavidS.Cooper,
M.D. (Johns Hopkins University School of Medicine), James
Korelitz, Ph.D. (Westat Research), Scott A. Rivkees, M.D.
(Yale University), John Senior, M.D. (FDA), Robert Squires
Jr., M.D., (University of Pittsburgh), Joslyn Swann, Pharm
D.,(FDA),andAnaSzarfman,M.D.(FDA).SurendraVarma,
M.D. represented the American Academy of Pediatrics
(AAP).
The following ATD-related information was evaluated:
published reports of AEs, FDA averse event reports (AERs),
prescribing practices, Pediatric Acute Liver Failure network
data, and OPTN UNOS liver transplantation data. Minutes
of this meeting are currently available [7]. The following
observations and estimates were made.
(1) The prevalence of GD in children in the United
States is about 1 in 10000 children. About 4000
pediatric patients per year with GD are being treated
with ATDs in the United States. In 2004, 40% of
children with GD were treated with PTU. Over the
past four years, the number of PTU prescriptions for
children with GD has decreased by about 50%, and
the number or prescriptions for MMI have increased
by about 50%.
(2) The risk of PTU-induced liver failure leading to
transplantation is about 1 in 2000–4000 children.
(About 0.5 PTU-related liver transplants per year
in children; ∼1000 to 2000 children per year taking
PTU.) Once PTU-induced liver failure occurs, it is
rapidly progressive with a low chance of reversibility.
The number of children developing PTU-induced
liver injury that is reversible is estimated to be at
leasttenfoldgreaterthanthenumberofchildrenwho
develop liver failure requiring transplantation.
(3) Routine biochemical surveillance of liver function
and hepatocellular integrity (serum bilirubin, alka-
line phosphatase and transaminase levels) will not be
useful in identifying children who will develop PTU-
induced liver failure.
(4) Children are at higher risk for PTU-induced liver
injury than adults.
(5) PTU-induced liver injury is an important concern
for the adult population. The number of adults with
GD is at least fourfold higher than the number of
children with GD. The proportion of adult patients
prescribed PTU for GD is currently greater than
the proportion of pediatric patients prescribed PTU.
Whereas the proportion of children prescribed PTU
for GD has decreased over the past four years, PTU
prescribing practices have remained steady in the
adult population.International Journal of Pediatric Endocrinology 3
Table 1: Case reports of propylthiouracil-related liver injury in pediatric patients.
Authors, year Age (years) Gender Daily dose (mg) Duration of PTU Liver abnormality Outcome
Moore, 1946 [8] 12 F 300 0.5 months Liver injury Recovery
Parker, 1975 [12] 9 F 300 2 months Portal inﬂammation cholestasis Recovery
Reddy, 1979 [14] 10 F 300 1.2 months Hepatitis Recovery
Bloch et al., 1985 [21] 12 M 450 2 months Hepatitis Recovery
Garty et al., 1985 [22] 12 F 300 1 month Hepatitis Recovery
Limaye and Ruﬀolo, 1987
[24]
6 F 300 4 months Hepatitis Recovery
Jonas and Eidson, 1988
[25]
13 F 300 7 months Massive necrosis Death
Baker et al., 1989 [26] 9 F 300 3 months Hepatitis Recovery
Kirkland, 1990 [29] 9 F 300 4 months Liver failure Transplant/Recovery
Levy, 1993 [31] 11 F 300 14 months Liver failure Death
Deidiker and deMello, 1996
[41]
13 F 250 4 months Liver failure Transplant/Death
Williams et al., 1997 [43] 14 F 450 4 months Liver failure Transplant/Recovery
Testa et al., 2003 [35] 17 F 450 6 months Liver failure Transplant/Recovery
Sipe et al., 2006 [37] 7 F 300 9 months Liver failure Transplant/Recovery
Table 2: Adverse events reported to the FDA from 1970 to 1997 in
individuals ≤18 years of age.
Adverse event Propylthiouracil Methimazole
Total number 34 14
Hospitalizations 18 3
Deaths 2 0
Liver injury: mild 1 0
Liver injury: serious 13 0
Liver transplantation 2 0
Liver injury-related death 2 0
Agranulocytosis 1 1
Leukopenia 3 1
Thrombocytopenia 1 0
Renal injury 3 0
Vasculitis 3 1
Arthritis 1 2
Arthralgia 1 1
Rash/urticaria 5 9
(6) MMI is not associated with a risk liver failure in the
pediatric population.
(7) PTU is associated with much higher risk of antineu-
trophil cytoplasmic antibody (ANCA) development
and vasculitis than MMI.
(8) PTU and MMI have comparable rates of agranulo-
cytosis (0.3% in adults). The risk of agranulocytosis
is dose-dependent with MMI but not with PTU. The
risk of agranulocytosis is very low with low doses of
MMI.
(9) MMI use during pregnancy is associated with an
increased risk of birth defects (aplasia cutis, choanal
atresia, esophageal atresia, tracheoesophagel ﬁstulas,
andathelia).PTUuseduringpregnancyisnotassoci-
ated with birth defects. Women should be informed
of the potential risks of PTU-hepatotoxity and risks
of MMI-associated fetal minor malformations when
considering ATD use during pregnancy.
(10) Even though there was more MMI than PTU use
in children over periods when PTU-induced liver
failure has been reported, there are no reports of liver
failure or liver transplants associated with MMI use
inchildren.TherearealsofewerandlessseriousAERs
in the FDA database for MMI than PTU.
(11) There is no good plan for managing hepatotoxicity
risk in a PTU-treated patient, other than not using
the drug.
7.The NeedtoConsiderAlternativestoPTU
Considering the above, we believe that PTU should never be
used as ﬁrst line treatment in children with GD [6, 65]. We
also believe that it is reasonable and prudent to discontinue
PTU use in the children taking this medication for the
treatment of GD.
In the United States and many countries, MMI is
available and should be considered as the alternative ATD
to PTU. In several countries, carbimazole [66], which is
converted to MMI, is available and should be considered as
the alternative ATD to PTU.
When using MMI in the treatment of GD, practitioners
should consider the following. In comparison with PTU,
MMI dosing is more convenient and associated with better
compliance [67], as the tablets are small (5 or 10mg), and4 International Journal of Pediatric Endocrinology
Table 3: Pediatric cohort studies of propylthiouracil-related adverse events.
Authors, year N AE (n) % AE Adverse events
Hamburger, 1985 [57] 182 31 17%
11 Cutaneous
1 Cutaneous and neutropenia
1 Cutaneous and rheumatological
1 Cutaneous and hepatic
1 Cutaneous and pharyngitis
4 Neutropenia
2H e p a t i c
1 Rheumatological
2N a u s e a
5 Multiple infections without neutropenia
1 Unspeciﬁed
Lippe et al., 1987 [59] 63 1 1.5% 1 Arthritic reaction
Ward et al., 1999 [62] 33 8 24% Rash, arthralgia, nausea, vomiting
Lazar et al., 2000 [63] 28 14 35% 2 Major; agranulocytosis; toxic hepatitis
12 Minor
Somnuke et al., 2007 [61]3 2 2 6 % ANCA; nephritis
Rash, arthralgia
Glaser and Styne, 2008 [56] 70 11 16%
1R a s h
2 Rash and arthralgia
1 Arthritis with purpura
1 Arthritis with purpura, hematuria
3 Elevated liver function tests
2 Marked elevated liver function tests
2 Neutropenia
Ma et al., 2008 [60] 40 8 20% 6 Serious
48 7 14.6% NA
MMI can be given once daily [4]. The MMI dose range
is typically used by our center is 0.1 to 0.3mg/kg per day,
with doses given once daily. Because MMI comes in 5 and
10mg tablets, which are small and diﬃcult to cut precisely,
we commonly prescribe the following doses: infants, 1.25mg
per day; 1 to 5 years, 2.5 to 5.0mg per day; 5 to 10 years,
5 to 10mg per day; 10 to 18 years, 10 to 20mg a day. With
severe hyperthyroidism (free T4 > 4ng/dL), doses 50% to
100% higher than above can be used.
Although MMI has a better overall safety proﬁle than
PTU, MMI is associated with minor adverse events that may
aﬀect up to 10% of children. MMI-related adverse events
include allergic reactions, rashes, myalgias, and arthralgias.
Agranulocytosis has been reported in about 0.3% of adult
patients taking MMI or PTU [4, 68, 69]. Agranulocy-
t o s i si sd o s e - d e p e n d e n tw i t hM M Ia n dr a r e l yo c c u r sa t
low doses [4, 68, 69]. When it develops, agranulocytosis
develops over the ﬁrst 100 days of therapy in 95% of
individuals [4, 68, 69]. Thus, if a patient taking MMI feels
ill for any reason, they should immediately discontinue
their medication and contact their physician. Although side
eﬀects to MMI most commonly occur within the ﬁrst 6
months of therapy, adverse events can occur with prolonged
therapy. In our clinical practice, we ﬁnd that 4% of children
on MMI developed adverse events after 18 months of
therapy.
The issue of how long ATDs should be used in children
before considering either radioactive iodine or surgery
warrants further study. Many practitioners will consider a
t r i a lo fA T D sf o ru pt ot w oy e a r sa n dp r o c e e dt os u r g e r yo r
radioactive iodine if remission (i.e., euthyroid after cessation
of ATDs) does not occur. Practitioners may also elect to
continue antithyroid medications for longer as long as toxic
reactions do not occur.
Properly administered, radioactive iodine is an accept-
able and eﬀective treatment for GD in the pediatric pop-
ulation [70]. The use of radioactive iodine in the pediatric
population, though, is viewed as controversial by some [71].
The goal of contemporary 131I therapy for GD is
hypothyroidism. Radioactive iodine should not be given to
make patients euthyroid, as this will result in remaining
partially-irradiated thyroid tissue, and it is recognized that
there is an increase risk of thyroid neoplasm when children
receive low doses of 131If o rG D[ 72, 73].
When used, >150uCi of 131I per gm of thyroid tissue
should be given to achieve thyroid ablation or hypothy-
roidism[70,74].Withlargeglands,higherdosesof 131I(200–
300uCi of 131I per gm) may be needed [74].International Journal of Pediatric Endocrinology 5
Table 4: UNOS data: number of recipients who received a liver
transplant from 01/01/90–06/30/08 due to PTU-induced liver fail-
ure. Over the same period, there were no MMI-related transplants.
Year
Age group Total
1–5 11–17 18–34 35–49 65+
N % N % N % N % N % N
1990 1 4.3 0 0 0 0 1 4.3 0 0 2
1991 0 0 0 0 1 4.3 0 0 0 0 1
1992 0 0 0 0 1 4.3 0 0 0 0 1
1993 0 0 1 4.3 0 0 2 8.7 0 0 3
1994 1 4.3 1 4.3 0 0 1 4.3 0 0 3
1995 0 0 0 0 1 4.3 0 0 0 0 1
1997 0 0 0 0 1 4.3 0 0 1 4.3 2
1998 0 0 0 0 1 4.3 0 0 0 0 1
1999 0 0 1 4.3 1 4.3 0 0 0 0 2
2000 0 0 0 0 1 4.3 0 0 0 0 1
2001 0 0 1 4.3 0 0 1 4.3 0 0 2
2004 0 0 0 0 2 8.7 0 0 0 0 2
2006 0 0 0 0 1 4.3 0 0 0 0 1
2007 0 0 1 4.3 0 0 0 0 0 0 1
Total 2 8.7 5 21.7 10 43.5 5 21.7 1 4.3 23
Because of theoretical concerns about whole body radi-
ation exposure associated with 131I, we feel that is prudent
to avoid radioactive iodine therapy in very young children,
that is, less than ﬁve years of age, and to avoid doses >10mCi
in children less ﬁve to ten years of age if possible. These
recommendations are based on theoretical concerns and
not “hard data.” Further studies are needed to deﬁne “how
young is too young.” It is recognized that there are special
circumstances in which 131I therapy may be required in
young children, for example, a young child has developed
a reaction to antithyroid medications, and proper surgical
expertise is not available, or the patient is not a suitable
surgical candidate.
Surgery is an acceptable form of therapy for GD
in children [71]. When performed, near total or total-
thyroidectomy is recommended [75]. We feel that surgery
is preferred in young children when deﬁnitive therapy is
required and can be performed by an experienced thyroid
surgeon. In individuals with large thyroid glands (>80gms),
the response to 131Iw i l lb ep o o r[ 76, 77], and surgery is
recommended for patients with large glands.
Recent national data show that surgical complication
rates are more common in children than adults, and
complications in children are more than twofold higher
when thyroidectomy in children is performed by pediatric
or general surgeons rather than by high volume thyroid sur-
geons [78]. Considering the intricacies of thyroidectomy in
c h i l d r e n ,i ti sr e c o m m e n d e dt h a tG Ds u r g e r yb ep e r f o r m e d
by experienced thyroid surgeons.
8. LimitedUse of PTU
There is no good plan for managing hepatotoxicity risk in
a PTU-treated patient, other than not using the drug [7].
However, when neither prompt surgery nor 131It r e a t m e n t s
are options in a patient who has developed a toxic reaction
to MMI, and antithyroid drug therapy is needed, short-term
PTU use can be considered.
Inthissituation,parentsandpatientsshouldbeinformed
of the risk of liver failure. If patients taking PTU develop
tiredness, nausea, anorexia, fever, pharyngitis, or feel ill,
the medication should be immediately discontinued by
the patient, a physician should be contacted, and a white
blood cell count, liver function tests, and transaminase
levels obtained. Alternatively, the hyperthyroid state can be
controlled for several weeks prior to surgery with saturated
potassium iodide solution (3 to 10 drops, p.o., tid).
Because MMI use during pregnancy is associated with
an increased risk of birth defects [79–81], whereas PTU
use during pregnancy is not, PTU is preferred during early
pregnancy. When used during pregnancy, women should
be informed of the potential risks of PTU-hepatotoxity and
risks of MMI-associated fetal minor malformations when
considering ATD selection during pregnancy.
9. Conclusions
PTU was introduced for clinical use in July 1947, and MMI
was introduced in June 1950. Over the six decades that
PTU has been used, reports of PTU-related liver failure
and death in children and adults have accumulated in
published literature and FDA databases. In comparison, we
are unaware of reports of death and liver failure in children
and adolescents taking MMI, and there are far fewer and
less serious adverse events reported for MMI than PTU in
general.
Perhaps in response to concerns that have been voiced
over PTU safety over the past several years [1, 4, 82], there
has been a gratifying reduction in PTU use in the pediatric
population over the past three years. Yet, it is likely that more
than1000pediatricpatientsarestilltakingPTUintheUnited
States. As such, it is estimated that at least one child will
develop PTU-induced liver failure requiring transplantation
overthenexttwoyearsifPTUusecontinuesatcurrentlevels.
Considering the above, we believe that PTU should never
be used as ﬁrst line treatment in children. PTU use should
onlybeconsideredinrarecircumstances,suchaspreparation
for surgery in a patient allergic to MMI or in pregnancy.
Current PTU use in children taking this medication
should be stopped in favor of alternate therapies to put
an end to PTU-induced liver failure in children. As such,
no child with GD should experience liver injury or failure,
require liver transplantation, or die due to PTU, from this
time forward.
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